Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma

Atezolizumab in combination with bevacizumab delayed time to deterioration of quality of life, physical functioning and role functioning compared with standard-of-care sorafenib as first-line treatment for unresectable hepatocellular carcinoma, according to patient-reported outcomes of the randomized phase 3 IMbrave 150 study scheduled for presentation at Gastrointestinal Cancers Symposium.The combination also appeared to delay appetite loss, fatigue, pain and diarrhea.“Because this combination demonstrated to be more efficacious than the previous standard of care and because it showedRead More

Share on facebook
Share on twitter
Share on linkedin